You are here

Article Text

Article menu

This article has a Reply. Please see:

Download PDFPDF
PostScript
Letter
Parenteral nutrition for preterm infants: correcting for arachidonic and docosahexaenoic acid may not suffice
  1. Wolfgang Bernhard1,
  2. Christian F Poets1,
  3. Axel Franz1,2
  1. 1 Department of Neonatology, University of Tübingen, Tübingen, Germany
  2. 2 Center for Pediatric Clinical Studies, University of Tübingen, Tübingen, Germany
  1. Correspondence to Dr Wolfgang Bernhard, Dept. of Neonatology, University of Tübingen, Tubingen, Baden-Württemberg, Germany; wolfgang.bernhard{at}med.uni-tuebingen.de

http://dx.doi.org/10.1136/archdischild-2021-321871

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In their review, Frazer and Martin1 address imbalanced supply with arachidonic (ARA) and docosahexaenoic acid (DHA) as central to preterm infant parenteral nutrition, advocating administration in adequate amounts and ratios, that fish oil containing suspensions corrupt physiological fatty acid profile and that supplying DHA without ARA is harmful to preterm infants <29 weeks. At 4 g/kg/d fat supply, SMOFlipid (2–7 mg/mL DHA) delivers 40–140 mg/kg/d DHA, but <10 mg/kg/d ARA (own unpublished data), contrasting with ~140–212 mg/kg/d ARA and ~43 mg/kg/d DHA physiological accretion during the third trimester. While we fully agree, additional aspects should be taken into account:

    1. The authors suggest an ARA:DHA ratio of 2:1, which was associated with superior outcome when compared with lower …

    View Full Text

    Footnotes

    • Contributors This letter’s first draft has been written by WB and was then extensively discussed and approved by all three authors.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles